Male breast cancer (MBC), accounting for < 1% of all breast malignancies, remains underrepresented in clinical trials evaluating human epidermal growth factor receptor 2 (HER2)-targeted therapies. This evidence concerns the gene ERBB2 and male breast carcinoma.